Neuropathic pain visiting card references

References for NPS MedicineWise educational visiting card for neuropathic pain

Card references

  1. International Association for the Study of Pain. IASP Taxonomy. Washington, DC: IASP, 2012 (accessed 10 August 2017).
  2. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73.
  3. Neurology Expert Group. Therapeutic Guidelines: Neuropathic pain. West Melbourne, Victoria: Therapeutic Guidelines Ltd, 2011 (accessed 10 August 2017).
  4. Martinez V, Attal N, Vanzo B, et al. Adherence of French GPs to chronic neuropathic pain clinical guidelines: results of a cross-sectional, randomized, "e" case-vignette survey. PLoS One 2014;9:e93855.
  5. Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 2016;157:1599-606.
  6. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152:14-27.
  7. Haanpää M, Treede R. Diagnosis and classification of neuropathic pain. Pain Clinical Updates 2010; XVIII.
  8. Haanpää ML, Backonja MM, Bennett MI, et al. Assessment of neuropathic pain in primary care. Am J Med 2009;122:S13-21.
  9. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers 2017;3:17002.
  10. Freynhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22.
  11. Bardin LD, King P, Maher CG. Diagnostic triage for low back pain: a practical approach for primary care. Med J Aust 2017;206:268-73.
  12. Hush JM, Marcuzzi A. Prevalence of neuropathic features of back pain in clinical populations: implications for the diagnostic triage paradigm. Pain Manag 2012;2:363-72.
  13. Maher C. Personal communication. 2017.
  14. Attal N, Perrot S, Fermanian J, et al. The neuropathic components of chronic low back pain: a prospective multicenter study using the DN4 Questionnaire. J Pain 2011;12:1080-7.
  15. Baron R, Binder A, Attal N, et al. Neuropathic low back pain in clinical practice. Eur J Pain 2016;20:861-73.
  16. IASP Taskforce onTaxonomy. Spinal Pain, Section 1: Spinal and Radicular Pain Syndromes in Classification of Chronic Pain. Seattle IASP Press, 2012 (accessed 22 September 2017).
  17. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009;13:185-90.
  18. Drug utilisation sub-committee. Pregabalin: 24 month predicted versus actual analysis (October 2015). Canberra: DUSC, 2015 (accessed 20 October 2017).
  19. Goodman CW, Brett AS. Gabapentin and pregabalin for pain — is increased prescribing a cause for concern? N Engl J Med 2017;377:411-4.
  20. Wettermark B, Brandt L, Kieler H, et al. Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract 2014;68:104-10.
  21. Fabritius ML, Strom C, Koyuncu S, et al. Benefit and harm of pregabalin in acute pain treatment: a systematic review with meta-analyses and trial sequential analyses. Br J Anaesth 2017;119:775-91.
  22. Olmedo-Gaya MV, Manzano-Moreno FJ, Galvez-Mateos R, et al. Oral pregabalin for postoperative pain relief after third molar extraction: a randomized controlled clinical trial. Clin Oral Investig 2016;20:1819-26.
  23. Baron R, Freynhagen R, Tolle TR, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010;150:420-7.
  24. Mathieson S, Maher CG, McLachlan AJ, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med 2017;376:1111-20.
  25. Romanò CL, Romanò D, Bonora C, et al. Pregabalin, celecoxib, and their combination for treatment of chronic low-back pain. J Orthop Traumatol 2009;10:185-91.
  26. Shanthanna H, Gilron I, Rajarathinam M, et al. Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. PLoS Med 2017;14:e1002369.
  27. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51.
  28. Endocrinology Expert Group. Therapeutic Guidelines: Endocrinology. Diabetic neuropathy. West Melbourne, Victoria: Therapeutic Guidelines Ltd, 2013 (accessed 16 August 2017).
  29. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 2010;85:S3-S14.
  30. Gilron I, Watson CP, Cahill CM, et al. Neuropathic pain: a practical guide for the clinician. CMAJ 2006;175:265-75.
  31. Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain 2015;156 Suppl 1:S104-14.
  32. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339.
  33. Mu A, Weinberg E, Moulin DE, et al. Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement. Can Fam Physician 2017;63:844-52.
  34. National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in nonspecialist settings. Clinical guidance (CG) 173. UK, 2013 (updated 2014) (accessed 20 October 2017).
  35. An update on the drug treatment of neuropathic pain. Part 1: antidepressants. Drug Ther Bull 2012;50:114-7.
  36. Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015:CD008242. https://www.ncbi.nlm.nih.gov/pubmed/26146793
  37. Meyer-Rosberg K, Kvarnstrom A, Kinnman E, et al. Peripheral neuropathic pain--a multidimensional burden for patients. Eur J Pain 2001;5:379-89.
  38. Smith BH, Torrance N, Bennett MI, et al. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007;23:143-9.
  39. Norrbrink C, Lofgren M. Needs and requests--patients and physicians voices about improving the management of spinal cord injury neuropathic pain. Disabil Rehabil 2016;38:151-8.
  40. Analgesic Expert Group. Therapeutic Guidelines: Analgesic. Chronic pain: nonpharmacological management. West Melbourne, Victoria: Therapeutic Guidelines Ltd, 2012 (accessed 15 August 2017).
  41. Turk DC, Audette J, Levy RM, et al. Assessment and treatment of psychosocial comorbidities in patients with neuropathic pain. Mayo Clin Proc 2010;85:S42-S50.
  42. Eccleston C, Hearn L, Williams AC. Psychological therapies for the management of chronic neuropathic pain in adults. Cochrane Database Syst Rev 2015:Cd011259.
  43. Dimitrova A, Murchison C, Oken B. Acupuncture for the treatment of peripheral neuropathy: A systematic review and meta-analysis. J Altern Complement Med 2017;23:164-79.
  44. Streckmann F, Zopf EM, Lehmann HC, et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44:1289-304.
  45. Gibson W, Wand BM, O'Connell NE. Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults. Cochrane Database Syst Rev 2017.
  46. Jones RC, 3rd, Lawson E, Backonja M. Managing neuropathic pain. Med Clin North Am 2016;100:151-67.
 

Insert references


  1. Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36.
  2. Haanpää M, Attal N, Backonja M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain 2011;152:14-27.
  3. Bouhassira D, Attal N. Diagnosis and assessment of neuropathic pain: the saga of clinical tools. Pain 2011;152:S74-83. 
  4. Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain 2016;157:1599-606.
  5. Haanpää M, Treede R. Diagnosis and classification of neuropathic pain. Pain Clinical Updates 2010; XVIII.
  6. Haanpää ML, Backonja MM, Bennett MI, et al. Assessment of neuropathic pain in primary care. Am J Med 2009;122:S13-21.
  7. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2017 (accessed 6 September 2017).
  8. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51.
  9. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73.
  10. Gilron I, Watson CP, Cahill CM, et al. Neuropathic pain: a practical guide for the clinician. CMAJ 2006;175:265-75.
  11. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339.
  12. Mu A, Weinberg E, Moulin DE, et al. Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement. Can Fam Physician 2017;63:844-52. 
  13. National Institute for Health and Care Excellence (NICE). Neuropathic pain in adults: pharmacological management in nonspecialist settings. Clinical guidance (CG) 173. UK, 2013 (updated 2014) (accessed 20 October 2017).
  14. Neurology Expert Group. Therapeutic Guidelines: Neuropathic pain. West Melbourne, Victoria: Therapeutic Guidelines Ltd, 2011 (accessed 10 August 2017).
  15. Attal N, Bouhassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain 2015;156 Suppl 1:S104-14.
  16. Expert Group. Pregabalin and gabapentin: advice for prescribers on the risk of misuse London: Public Health England and NHS England, 2014 (accessed 14 September 2017).
  17. Pfizer Australia Pty Ltd. Neurontin Product Information. 2017.
  18. Gomes T, Juurlink DN, Antoniou T, et al. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. PLoS Med 2017;14:e1002396.
  19. Gahr M, Freudenmann RW, Hiemke C, et al. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol 2013;69:1335-42.
  20. Pfizer Australia Pty Ltd. Lyrica Product Information. 2016.
  21. NPS MedicineWise. Tapentadol sustained release (Palexia SR) for chronic, severe disabling pain. RADAR 2014. 
  22. bioCSL Pty Ltd. VERSATIS (Lignocaine) 5% w/w, Dermal Patch Product Information. 2015.
  23. Lakhan SE, Velasco DN, Tepper D. Botulinum Toxin-A for painful diabetic neuropathy: A meta-analysis. Pain Med 2015;16:1773-80.